Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study
Neil D. Gross(The University of Texas MD Anderson Cancer Center), David M. Miller(Massachusetts General Hospital), Nikhil I. Khushalani(Moffitt Cancer Center), Vasu Divi(Stanford University), Emily S. Ruiz(Harvard University), Evan J. Lipson(Bloomberg (United States)), Friedegund Meier(Technische Universität Dresden), Yungpo Bernard Su(Nebraska Cancer Specialists), Paul Swiecicki(University of Michigan), Jennifer Atlas(Levine Cancer Institute), J.L. Geiger(Cleveland Clinic), Axel Hauschild(University of Lübeck), Jennifer H. Choe(Duke Cancer Institute), Brett Hughes(Royal Brisbane and Women's Hospital), Dirk Schadendorf(Essen University Hospital), Vishal Patel(George Washington University), Jade Homsi(The University of Texas Southwestern Medical Center), Janis M. Taube(Johns Hopkins Hospital), Annette M. Lim(The University of Melbourne), Renata Ferrarotto(The University of Texas MD Anderson Cancer Center), Suk‐Young Yoo(Regeneron (United States)), Melissa Mathias(Regeneron (United States)), Hyunsil Han(Regeneron (United States)), Frank Seebach(Regeneron (United States)), Israel Lowy(Regeneron (United States)), Matthew G. Fury(Regeneron (United States)), Danny Rischin(Peter MacCallum Cancer Centre)
Cited by 96
Abstract
Related Papers
No related papers found
Powered by citation graph analysis